Research Use Only - Not for human consumption. 18+ only.

Vilon vs Pinealon

Evidence-based comparison · Updated 2026

Summary

Vilon targets thymus and immune system function, making it the more relevant choice for immune support and age-related immune decline. Pinealon targets the brain and pineal gland, making it better suited for cognitive protection and circadian regulation. Choose Vilon for immune and thymic concerns, and Pinealon for neurological and memory-related research goals.

Side-by-Side Comparison

VilonPinealon
EvidenceCGrade CPrimarily animal or in-vitro studies; limited human dataCGrade CPrimarily animal or in-vitro studies; limited human data
RegulatoryResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use onlyResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Benefits
  • +Regulates immune system
  • +Anti-aging effects
  • +Supports thymus health
  • +May normalize cortisol
  • +Improves stress response
  • +Neuroprotective effects
  • +Improves memory and learning
  • +Supports brain health
  • +May reduce cognitive decline
  • +Regulates circadian rhythm
Dosage10 mg mg — Daily for 5-10 days per month10 mg mg — Daily for 10-20 days per month
RouteSubcutaneous, OralSubcutaneous, Oral
CategoryKhavinson BioregulatorsKhavinson Bioregulators

Which Should You Choose?

Vilon acts primarily on the immune and endocrine axis through thymic peptide signaling, while Pinealon operates on the neuroendocrine axis by supporting pineal gland function and melatonin regulation. Their target tissues are largely distinct, which makes the choice between them highly dependent on the system under investigation.

Choose Vilon when:

  • +Research focus involves thymus function or age-related immune decline
  • +Interest in immune cell differentiation and homeostasis in aging models
  • +Investigating cortisol normalization or stress response modulation through immune pathways

Choose Pinealon when:

  • +Research focus involves cognitive decline, memory, or neuroprotection
  • +Interest in circadian rhythm disruption and melatonin-related signaling
  • +Investigating oxidative stress in central nervous system tissue or sleep quality in aging models

Stacking Vilon and Pinealon is occasionally explored in longevity-focused Khavinson bioregulator protocols, as they address complementary systems, the immune and neuroendocrine axes, without known pharmacological overlap or antagonism.

Frequently Asked Questions

Can Vilon and Pinealon be used together in the same research protocol?
Research on Khavinson bioregulators suggests that peptides targeting different organ systems can be combined without direct mechanistic interference. Vilon acts on the thymus and immune system, while Pinealon acts on the brain and pineal gland, so their physiological targets do not overlap significantly. Combined use is seen in some Russian gerontology research as part of multi-peptide bioregulator protocols, though controlled comparative data on co-administration is limited.
Do Vilon and Pinealon have different onset timelines in research settings?
Both peptides are short-chain Khavinson bioregulators, but their effect timelines differ by target system. Pinealon's influence on circadian rhythm and sleep-related markers may be observed over shorter observation windows in some studies, while Vilon's immunomodulatory effects, particularly changes in thymic output or immune cell profiles, may require longer dosing periods to become measurable. Neither peptide has established standardized timelines in human clinical research due to limited regulatory-grade trials.
Which peptide is more relevant for general anti-aging research, Vilon or Pinealon?
Both peptides have been investigated in the context of aging, but they address different mechanisms of age-related decline. Vilon is more relevant when the anti-aging focus is on immune senescence and thymic involution, processes that are well-documented contributors to aging. Pinealon is more relevant when the focus is on neurological aging, cognitive decline, or disrupted circadian biology, which are also central to the aging phenotype. Neither has a definitive evidence advantage over the other, as both carry a Grade C evidence rating.
Is there any functional overlap between Vilon and Pinealon that would make choosing one redundant?
Functional overlap between Vilon and Pinealon appears minimal based on current research. Vilon's primary signaling is directed at thymic and immune pathways, while Pinealon's is directed at neuroendocrine and neuroprotective pathways. Some indirect crosstalk may exist, since immune function and neurological health are broadly interconnected in aging biology, but neither peptide is considered a substitute for the other. Selecting one over the other based on the specific system of interest is the more rational approach in a research context.

Not sure which fits your research goals?

Use the Goal Finder

Answer 3 questions and get a personalised peptide recommendation ranked by evidence grade.

Find My Peptide →